中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (6): 429-432.doi: 10.12144/zgmfskin202506429

• 临床研究 • 上一篇    下一篇

阿普米司特治疗掌跖脓疱病疗效及安全性评价

姚心怡1,葛曼2,刘绿野1,张峻岭2   

  1. 1天津中医药大学研究生院，天津，301617； 2天津市中医药研究院附属医院，天津，300120
  • 出版日期:2025-06-15 发布日期:2025-05-23

Efficacy and safety of apremilast in the treatment of palmoplantar pustulosis

YAO Xinyi1, GE Man2, LIU Lyuye1, ZHANG Junling2   

  1. 1 Graduate School of Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; 2 Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin 300120, China
  • Online:2025-06-15 Published:2025-05-23

PDF (PC)

5

摘要： 目的：评价阿普米司特治疗掌跖脓疱病（PPP）的疗效和安全性。方法：回顾性分析2023年4月至2024年4月我院皮肤科接受阿普米司特治疗的8例中重度PPP患者的临床资料。纳入标准为年龄≥18岁、PPP病程≥6个月且PPPASI≥15，既往系统治疗疗效欠佳。采用PPPASI、NRS、PGA、DLQI评分评估疗效，实验室检查评估安全性。结果：治疗前患者PPPASI、NRS、PGA、DLQI评分分别为25.50±9.35、6.50±1.58、3.88±0.78、21.13±2.85，治疗16周后分别为3.25±2.97、0.75±1.09、1.13±0.92、5.63±3.28，差异均有统计学意义（均P<0.05）。治疗期间8例患者的实验室指标均无明显异常,未出现严重不良事件。结论：阿普米司特治疗中重度PPP安全有效。

关键词: 掌跖脓疱病, 阿普米司特, 磷酸二酯酶4抑制剂

Abstract: Objective: To evaluate the clinical efficacy and safety of apremilast in patients with palmoplantar pustulosis (PPP) . Methods: The clinical data of 8 patients with moderate-to-severe PPP who received apremilast in the dermatology clinic from April 2023 to April 2024 were analyzed retrospectively. The inclusion criteria included age≥18 years, disease duration of PPP≥6 months, and PPPASI score≥15, poor response to previous systemic therapies. The efficacy was assessed through the PPPASI, NRS, PGA, and DLQI scores, while the safety was evaluated through laboratory tests. Results: Before the treatment, the patients' PPPASI, NRS, PGA, and DLQI scores were 25.50±9.35, 6.50±1.58, 3.88±0.78, and 21.13±2.85, respectively. After 16 weeks of treatment, the scores decreased to 3.25±2.97, 0.75±1.09, 1.13±0.92, and 5.63±3.28, respectively. There were significant differences of these between and after treatment (Ps<0.05). During the treatment period, there were no significant abnormalities in the laboratory indexes of the 8 patients, and no serious adverse events occurred. Conclusions: Apremilast is safe and effective in the treatment of moderate-to-severe PPP.

Key words: palmoplantar pustulosis, apremilast, PDE-4 inhibitor